| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-63267-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-11758-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-11759-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-11758 | |||
| Azide and BSA Free | NBP2-11758-0.025mg | |||
![Flow Cytometry: KIR/CD158 Antibody (NKVFS1) [NB100-63267] - Staining of human peripheral blood lymphocytes.](http://images.novusbio.com/fullsize/KIR-CD158-Antibody-NKVFS1-Flow-Cytometry-NB100-63267-img0001.jpg "Flow Cytometry: KIR/CD158 Antibody (NKVFS1) [NB100-63267] - Staining of human peripheral blood lymphocytes.")
![Flow Cytometry: KIR/CD158 Antibody (NKVFS1) [NB100-63267] - Staining of human peripheral blood lymphocytes using KIR PE.](http://images.novusbio.com/fullsize/KIR-CD158-Antibody-NKVFS1-Flow-Cytometry-NB100-63267-img0002.jpg)
![Western Blot: KIR2DL1/CD158a Antibody (2F9) [NBP1-04315] - Recombinant human protein KIR2DL1, KIR2DL3, KIR2DS4 and KIR2DL4 (each 50ng per well) were resolved by SDS-PAGE, transferred to PVDF membrane and probed with anti-human KIR2DL1 (1:500). Proteins were visualized using a goat anti-mouse secondary antibody conjugated to HRP and an ECL detection system.](http://images.novusbio.com/fullsize/KIR2DL1-CD158a-Antibody-2F9-Western-Blot-NBP1-04315-img0002.jpg "Western Blot: KIR2DL1/CD158a Antibody (2F9) [NBP1-04315] - Recombinant human protein KIR2DL1, KIR2DL3, KIR2DS4 and KIR2DL4 (each 50ng per well) were resolved by SDS-PAGE, transferred to PVDF membrane and probed with anti-human KIR2DL1 (1:500). Proteins were visualized using a goat anti-mouse secondary antibody conjugated to HRP and an ECL detection system.")
![Flow Cytometry: KIR2DL1/CD158a Antibody (HP-MA4) [NBP2-62191] - Surface staining of human peripheral blood with anti-CD158a/g/h (HP-MA4) PE.](http://images.novusbio.com/fullsize/KIR2DL1-CD158a-Antibody-HP-MA4-Flow-Cytometry-NBP2-62191-img0002.jpg "Flow Cytometry: KIR2DL1/CD158a Antibody (HP-MA4) [NBP2-62191] - Surface staining of human peripheral blood with anti-CD158a/g/h (HP-MA4) PE.")
![Flow Cytometry: KIR2DL1/CD158a Antibody (HP-MA4) [NBP2-62191] - Surface staining of human peripheral blood with anti-CD158a/g/h (HP-MA4) purified / GAM-APC.](http://images.novusbio.com/fullsize/KIR2DL1-CD158a-Antibody-HP-MA4-Flow-Cytometry-NBP2-62191-img0001.jpg)
![Flow Cytometry: KIR2DL1/KIR2DS5 Antibody (124) [NBP2-90181] - Flow cytometric analysis of Human KIR2DL1(CD158a) expression on human whole blood lymphocytes. Cells were stained with purified anti-Human KIR2DL1(CD158a), then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes.](http://images.novusbio.com/fullsize/KIR2DL1-KIR2DS5-Antibody-124-Flow-Cytometry-NBP2-90181-img0001.jpg "Flow Cytometry: KIR2DL1/KIR2DS5 Antibody (124) [NBP2-90181] - Flow cytometric analysis of Human KIR2DL1(CD158a) expression on human whole blood lymphocytes. Cells were stained with purified anti-Human KIR2DL1(CD158a), then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes.")